Medovate Signs Exclusive Agreement with Vygon to Distribute SAFIRA

RAYUS Radiology Quality Institute Distinguished Nationally by Centers for Medicare & Medicaid

Quality Institute Again Earns Certification as Provider-Led Entity for Advanced Diagnostic Imaging Guidance to Clinicians.

LX1550 Multiparameter Remote Monitoring Platform Receives FDA 510 (k) Approval: Reports LifeSignals

Further validation of ability to deliver continuous remote patient vital signs monitoring within both hospital and home settings.

U.S. News & World Report Names Tampa General Hospital as Best in Tampa Bay

This is the sixth consecutive year that Tampa General has been named by U.S. News & World Report as Tampa Bay's top hospital.

October 19, 2020

Medovate, a dynamic medical device company dedicated to the development and commercialization of innovative medical technologies, and Vygon Group, a group specializing in single-use medical devices, today announce that they have signed an exclusive deal to distribute SAFIRA® (SAFer Injection for Regional Anaesthesia) across 60 countries. Vygon will start a phased launch of SAFIRA in Europe at the end of 2020, with other global markets to follow.

Medovate notes SAFIRA, developed in collaboration with UK National Health Service (NHS) clinicians, transforms the technique of Peripheral Nerve Blockade into a one-person procedure, giving the anesthetist full control of the injection at all times. This pioneering technology also improves patient safety by helping reduce the risk of nerve damage, as it prevents anesthetic from being injected at high pressures. Furthermore, economic modelling has shown SAFIRA has the potential to help generate significant time and cost savings in a medical setting.

Amid the current COVID-19 pandemic, the European Society for Regional Anaesthesia (ESRA) has recommended that regional anesthesia be considered whenever surgery is planned for a suspected or confirmed COVID-19 patient. Regional anesthesia preserves respiratory function and avoids aerosolization and the potential for transmission of COVID-19, compared to general anesthesia. By making regional anesthesia a one-person procedure SAFIRA helps hospitals meet these recent recommendations.

Vygon is one of the largest independent French medical device companies. It supplies more than 205 million products globally per year. A world-leader in the regional anesthesia arena, it is perfectly placed to ensure SAFIRA – which recently attained EU CE regulatory approval – achieves its maximum reach and potential across Europe and beyond. Medovate is a medtech company that develops essential new technologies created through its development pipeline of NHS innovations, with a focus on anesthesia, airway, critical care, and surgery.

“This agreement with Vygon marks a significant milestone in the launch of SAFIRA across Europe, the US, and a number of other markets,” said Stuart Thomson, Managing Director, Medovate. “This will help establish Medovate on the world stage as a recognized medical device developer and manufacturer. In addition, it raises the international profile of the UK NHS and its clinicians, who are key stakeholders in Medovate and inventors of the SAFIRA innovation.”

“This is a very exciting partnership for Vygon,” said John Kerridge, Vice President, Anaesthesia & Emergency Business Unit, Vygon. “The SAFIRA technology, in terms of its impact on patient safety and clinical end-user efficiency, is in-line with our overall objective of patient/practitioner-based healthcare solutions. The fact that in the very near future the SAFIRA technology will be available in NRFit format further supports this objective. It will enable us to offer a complete NRFit solution for those markets that demand it.”

NRFit (trademark of GEDSA) devices provide dedicated connectors, compliant with ISO 80369-6. NRFit connectors aim to reduce the risk of wrong route administration of medications associated with Regional Anaesthesia procedures.

It is estimated that ten million regional anesthesia procedures are performed across Europe every year. As the use of regional anesthesia continues to grow steadily across Europe, SAFIRA has the potential to make a significant impact.




Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.